April's 10 most-bought funds
6th May 2016 16:00
by Kyle Caldwell from interactive investor
Share on
Investors have been reducing their exposure to equity funds since the start of the year, but demand for "star" fund managers has not cooled, with both Terry Smith and Neil Woodford taking top positions among the most-bought funds on the Interactive Investor platform in April.
It is the second time this year Smith, who runs (one of our sister magazine Money Observer's Rated Funds), has taken the top spot.
Woodford's open-ended fund, , was second in the popularity stakes. It has regularly held the top spot since launch in June 2014.
Outside of the top two, there were plenty of changes within the top 10, with two new names entering: and , jumping from 15th and 16th place respectively last month. Both are Money Observer Rated funds.
Changes
The two funds that exited the top 10 were , managed by Mark Barnett, and , a tracker fund.
In third place overall was Money Observer Rated Fund , a strong performer over the past five years, returning 66%. This is comfortably ahead of the average global sector fund return of 39%.
The other five funds that kept their place in the top 10 were , , , and .
UK equity funds dominated the remainder of the top 20, including Rated Funds and .
| April's 10 most-bought funds | |||||
|---|---|---|---|---|---|
| Rank | Fund | IA sector | Change since March | Total return 1m to 5 May (%) | Total return 3yr to 5 May (%) |
| 1 | Fundsmith Equity* | Global | 1 | -2.1 | 58.2 |
| 2 | CF Woodford Equity Income | UK equity income | -1 | -1.4 | N/A |
| 3 | Artemis Global Income* | Global equity income | 1 | -2.6 | 28.5 |
| 4 | Marlborough UK Micro Cap Growth* | UK smaller companies | 11 | 1.1 | 55.4 |
| 5 | Invesco Perpetual Income* | UK equity income | 4 | -0.8 | 25.3 |
| 6 | HSBC FTSE 250 Index | UK all companies | -1 | -0.7 | 27.5 |
| 7 | Newton Global Income* | Global equity income | 9 | -2.9 | 29.7 |
| 8 | Vanguard LifeStrategy 80% Equity | Mixed investment 40-85% shares | -5 | -0.3 | 18.6 |
| 9 | Axa Framlington Biotech* | Specialist | -3 | -2.9 | 66 |
| 10 | Lindsell Train Global Equity* | Global | -2 | -1.8 | 44.4 |
| *denotes a Money Observer Rated Fund | |||||
This article is for information and discussion purposes only and does not form a recommendation to invest or otherwise. The value of an investment may fall. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment adviser.